Cell Press posts cancer therapy study
- Cell published a pan-cancer proteogenomics study mapping new drug targets by combining tumor DNA, protein data and lab screens across 1,043 patients. - The researchers analyzed 10 cancer types and linked hidden protein and peptide targets to drug repurposing, immunotherapy and follow-up validation experiments. - The work widens precision oncology beyond DNA mutations alone. (cell.com)
Cancer drugs are usually built around DNA mutations, but tumors run on proteins — the molecules genes actually make and cells actually use. (cell.com 1) (cell.com 2) A Cell study pulled those layers together across 1,043 patients in 10 cancer types, combining proteogenomic data, cancer cell-line screens and tumor-antigen predictions. (cell.com) Proteogenomics means reading the genome and then checking which proteins and protein fragments actually appear in tumors. That can expose targets that DNA sequencing alone misses. (cell.com) (cancer.gov) The Cell team reported a broader map of therapeutic candidates, including proteins that could fit drug-repurposing strategies and peptides that could serve as tumor antigens. (cell.com) That matters in cancer because many tumors share the same mutation on paper but behave differently once their proteins are switched on, modified or broken down. (cell.com 1) (cell.com 2) The National Cancer Institute said the study points to “much, much bigger” target space than researchers are currently pursuing, and noted that lab tests slowed cancer-cell growth when some predicted targets were blocked. (cancer.gov) The same logic sits behind newer efforts to reach “undruggable” cancer proteins — targets that small-molecule drugs and antibodies have struggled to bind directly. One approach is targeted protein degradation, which marks a protein for the cell’s disposal machinery instead of trying to inhibit it. (cell.com 1) (cell.com 2) Another line of work uses artificial intelligence to design proteins with new jobs, including proteins that can help immune cells recognize and attack tumors more effectively. (sciencenews.org) (cell.com) Gene editing is a separate tool in the same broader push: instead of targeting a protein after it appears, researchers try to rewrite or regulate the cancer-driving instruction set itself. Reviews in Cell journals describe CRISPR-based strategies for engineered immune cells, mutant-gene targeting and programmable anti-cancer circuits. (cell.com) (cell.com) What the new proteogenomics map adds is a way to decide which of those tools might fit which tumor. It shifts the search from “Which mutation is present?” to “Which protein target is actually active, exposed and vulnerable here?” (cell.com) (cell.com) The immediate result is not a new approved therapy. It is a larger, more specific parts list for drug makers and cancer labs trying to turn hidden tumor biology into treatments. (cell.com) (cancer.gov)
